













http://dx.dCytomegalovirus Reactivation Following Autologous
Peripheral Blood Stem Cell Transplantation for
Multiple Myeloma in the Era of Novel
Chemotherapeutics and Tandem Transplantation
Jong Hun Kim,1 Claudia Goulston,1 Stephanie Sanders,2 Mary Lampas,2
Maurizio Zangari,3 Guido Tricot,4 Kimberly E. Hanson1Cytomegalovirus (CMV) is an important pathogen after allogeneic transplantation. However, few studies
have examined CMV reactivation after autologous peripheral blood stem cell transplantation (APBSCT)
to treat multiple myeloma (MM), especially in the setting of the newer chemotherapeutic agents and/or 2
sequential APBSCTs (ie, tandem transplantation). A retrospective chart review of patients with MMwho un-
derwent either single APBSCTor tandem transplantation was conducted to evaluate the incidence, risk fac-
tors, and outcomes of CMV infection at a single institution. A total of 104 patients with MM underwent
transplantation during the study period, including 66 patients who received tandem transplantation. The ma-
jority of patients (66 of 104; 63.5%) were CMV-seropositive, and CMV viremiawas frequently detected in this
subgroup (32 of 66; 48.5%). No primary CMV infections were identified. CMV reactivation was more com-
mon in recipients of tandem transplantation than in recipients of single APBSCT (P\.001). In addition, pa-
tients who developed CMV viremia were more likely to have received conditioning therapy with melphalan,
bortezomib, dexamethasone, and thalidomide compared with those without CMV reactivation (P 5 .015).
However, on multiple logistic regression analysis, only receipt of tandem transplantation was significantly as-
sociated with CMV reactivation (odds ratio, 5.112; 95% confidence interval, 1.27-20.60; P 5 .022). Febrile
episodes of CMV viremia were observed in 17 patients (17 of 32; 53.1%), and invasive CMV disease was
diagnosed in 1 patient. Our data suggest that CMV reactivation after APBSCT for MM is relatively common,
and that viremia is often associated with fever. CMV surveillance should be considered, especially when
tandem transplantation is performed using combination chemotherapy with high-dose melphalan.
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Multiple myeloma (MM) accounts for 15% of all
new cases of hematologic malignancy diagnosed in
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logous peripheral blood stem cell transplantation
(APBSCT) has significantly improved survival rates
compared with conventional chemotherapy alone [2].
Recently, additional advances in MM treatment have
had a positive impact on both disease-free and overall
survival. These advances include the use of novel
chemotherapeutic agents (eg, bortezomib, thalido-
mide, and lenalidomide), as well as more intensive
transplantation regimens that involve 2 sequential
APBSCTs (ie, tandem transplantation) [3-5]. These
treatments also result in a heightened net state of
immunosuppression, which increases susceptibility to
opportunistic infections [6].
Theprevalenceof activecytomegalovirus (CMV) in-
fection is lower after conventional single APBSCT than
after allogeneic transplantation [7,8]; however, little is
known about the overall incidence of active CMV
infection in patients with MM receiving more intensive
treatment regimens. We performed a retrospective,1753
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and outcomes of CMV infection in patients with MM
who underwent sequential tandem transplantation with
a high-dose melphalan-based regimen combined with
novel chemotherapeutics.PATIENTS AND METHODS
This study involved an Institutional Review
Board–approved retrospective review of all patients
with MM who underwent APBSCT between October
2007 and February 2009 at the Huntsman Cancer
Institute at the University of Utah, a tertiary care,
comprehensive cancer facility with an active stem cell
transplantation program. Patient data were reviewed
for 1 year after single APBSCT or the first APBSCT
of a planned tandem transplantation.
Clinical variables included baseline demographic
data, such as CMV serostatus (ie, CMV IgG), age, sex,
comorbidities, serum creatinine level (.1.4 mg/dL
or#1.5 mg/dL), multiple myeloma stage as defined by
the International Staging System [9], receipt of mainte-
nance chemotherapy within 6 months of the initial
APBSCT, history of previous transplantation, preinitial
APBSCTCD41Tcell count, conditioning chemother-
apy for both the initial and secondAPBSCT,occurrence
of othermicrobiologically confirmed bacterial or fungal
infections within 30 days of the initial and/or second
APBSCT, as well as the duration of neutropenia
(defined as an absolute neutrophil count\500 cells/mL).
CD341-selected peripheral blood stem cells
(PBSCs)weremobilizedwith either recombinant gran-
ulocyte colony-stimulating factor (Amgen, Thousand
Oaks, CA) alone or chemotherapy (ie, dexamethasone,
cisplatin, adriamycin, cyclophosphamide, and etopo-
side) followed by granulocyte colony-stimulating
factor. The conditioning regimens for the initial trans-
plantation consisted of melphalan (M) only; M, borte-
zomib (B), dexamethasone (D), and thalidomide (T)
(M/B/D/T); orM/B/D/gemcitabine (G), with or with-
out carmustine (C) (M/B/D/G1/2C). The latter 2
combinations were also used for the second APBSCT
in tandem transplantations. The treating physician
selected the conditioning regimen and determined
whether the patient underwent single or tandem
transplantation.
CMV serostatus was determined for all patients
before transplantation using a chemiluminescent
immunoassay (Immulite CMV IgG; Siemens, Tarry-
town, NY). Routine CMV surveillance was performed
weekly after transplantation with an in-house-devel-
oped quantitative real-time polymerase chain reaction
(PCR) CMV assay (ARUP Laboratories, Salt Lake
City, UT). Weekly monitoring was continued until
the patient was placed on maintenance chemotherapy,
followed by testing every 3 months and/or on the de-
velopment of signs and symptoms suggesting activeCMV infection. The quantitative range of this assay
was 2.6-6.6 log10 copies/mL. In the presence of evi-
dence of CMV viremia, as defined by the detection
of CMV DNA in 2 sequential plasma specimens, pre-
emptive anti-CMV therapy was initiated at the treat-
ing physician’s discretion.
Statistical analyses were performed using SPSS
version 15.0 for Windows (SPSS Inc., Chicago, IL).
Dichotomous variables were compared using the Pear-
son c2 test or Fisher exact test. For continuous vari-
ables, the Mann-Whitney U test was used. Variables
with a P value\.20 on comparison analysis were in-
cluded in a stepwise logistic regression model. Multi-
variate logistic regression was used to determine
factors associated with CMV viremia. Odds ratios
and 95% confidence intervals were calculated. A
P value \.05 was considered to indicate statistical
significance.RESULTS
During the study period, a total of 104 patients
with MMwere treated with APBSCT. The study pop-
ulation was predominantly white (92.3%) and male
(72.1%), and had a median age of 61 years (interquar-
tile range [IQR], 53-67). The majority of patients
(93 of 104; 89.3%) received dexamethasone, cisplatin,
adriamycin, cyclophosphamide, and etoposide chemo-
therapy for PBSC mobilization. Thirty-eight patients
(36.5%) underwent single APBSCT using of one of
the following conditioning regimens: M alone
(n 5 5), M/B/D/T (n 5 24), or M/B/D/G1/2C
(n5 9). The remaining 66 patients (63.4%) underwent
tandem transplantation using M alone (n 5 2), M/B/
D/T (n 5 63), or M/B/D/G1/2C (n 5 1) as
conditioning for the first transplantation and either
M/B/D/T (n 5 59) or M/B/D/G1/2C (n 5 7) for
the second transplantation. The median time between
the first and the second transplantation of a tandem
APBSCT was 88 days (IQR, 81-101 days).
Sixty-six of the 104 patients (63.4%) were CMV
IgG-positive before APBSCT. No cases of primary
CMV infection were identified among the CMV-
seronegative patients during the first year after
APBSCT. Overall, 48.5% (32 of 66) of CMV-
seropositive patients developed at least one episode
of CMV viremia. Active CMV infection developed in
18.2% (4 of 22) of the seropositive single APBSCT
recipients, compared with 63.6% (28 of 44) of the tan-
dem APBSCT recipients, a statistically significant dif-
ference in proportion (P\ .001). Of the patients who
underwent tandem transplantation, 11 (25%) devel-
oped CMV viremia after the first transplantation,
9 (20.5%) did so after the second transplantation,
and 8 (18.2%) did so after both transplantations. The
time from stem cell infusion to the development of
CMV viremia ranged from 8 days to 26 days.
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reactivation status for comparison analysis (Table 1).
Tandem transplantation and receipt of M/B/D/T
were more common in the patients who developed
CMV reactivation than in those who did not
(P\ .001 and .015, respectively). There was an inverse
relationship between a history of previous APBSCT
and CMV reactivation. A history of previous APBSCT
for MM was less common in patients with CMV reac-
tivation than in those without CMV reactivation (3 of
32 [9.4%] versus 15 of 34 [44.1%]; P 5 .002). Among
the 18 patients with a previous APBSCT, 10 received
a single APBSCT and 8 underwent tandem transplan-
tation during the study period. The median time be-
tween previous APBSCT and the initial
transplantation of this study was 30 months (IQR,
21-50 months). There were no significant differences
in the duration of neutropenia, presence of other con-
firmed bacterial or fungal infections, or all-cause mor-
tality between patients with and those without CMV
reactivation. Multiple logistic regression analysis wasTable 1. Characteristics of the CMV-Seropositive Patients*
CMV
Nonreactivation
(n 5 34; 51.5%)
CMV
Reactivation
(n 5 32; 48.5%) P
Previous APBSCT, n (%) 15 (44.1) 3 (9.4) .002
Chemotherapy within
previous 6 months, n (%)†
16 (47.1) 13 (40.6) .599
Age, years, median (IQR) 62 (53-68) 62 (54-68) .959
Males, n (%) 24 (70.6) 19 (59.4) .339
Females, n (%) 10 (29.4) 13 (40.6)
Other medical conditions, n (%)
HIV or solid organ
transplant recipient
0 (0.0) 1 (3.1) .485
Diabetes mellitus 4 (11.8) 4 (12.5) 1.000
Renal insufficiency‡ 3 (8.8) 2 (6.3) 1.000
MM disease stage, n (%)
Stage 1 8 (23.5) 4 (12.5) .246
Stage 2 8 (25.5) 6 (18.8) .635
Stage 3 18 (52.9) 22 (68.8) .189
CD4+ T cell count,
median (IQR)
153 (87-367) 212 (133-320) .334
Conditioning regimen, n (%)
M 4 (11.8) 2 (6.3) .673
M/B/D/T 24 (70.6) 30 (93.8) .015
M/B/D/G+/2C 6 (17.6) 0 (0.0) .025
Duration of neutropenia, days,
median (IQR)§
8 (7-8) 8 (6-9) .635
Other infection within 30 days,
n (%)jj
12 (35.3) 15 (46.9) .339
Tandem autologous stem cell
transplantation, n (%)
16 (47.1) 28 (87.5) <.001
Overall mortality, n (%)¶ 3 (8.8) 3 (9.4) 1.000
*Age, other medical conditions, MM disease stage, and median CD4+
cell count reflect baseline characteristics at single or first APBSCT of
tandem transplantation.
†Receipt of chemotherapy in the 6 months before transplantation for in-
dications other than stem cell collection.
‡Renal insufficiency defined as serum creatinine >1.5 mg/dL.
§Neutropenia defined as absolute neutrophil count <500 cells/mL after
single or first APBSCTof tandem transplantation.
jjConfirmed bacterial or fungal infection within 30 days of single or first
APBSCTof tandem transplantation.
¶Death from any cause by the end of 1-year follow-up.performed using variables with a P value\.20 on com-
parison analysis (Table 2). In this model, only receipt
of tandem transplantation was significantly associated
with CMV reactivation (odds ratio, 5.11; 95% confi-
dence interval, 1.27-20.60; P 5 .022).
CMV reactivation was further classified according
to the timing of onset of viremia (Table 3). Group 1
reactivated CMV after a single APBSCT (n 5 4),
group 2 reactivated CMV only after the first transplan-
tation of a tandem APBSCT (n 5 11), group 3 reacti-
vated CMV only after the second transplantation of
a tandem APBSCT (n 5 9), and group 4 reactivated
CMV after both the first and the second transplanta-
tions of a tandem APBSCT (n5 8). The median dura-
tion of neutropenia and other infectious complications
were similar across the 4 groups. Median peak CMV
DNA was highest after the second transplantation, es-
pecially in those patients with reactivated CMV after
the first transplantation.
Approximately one-half of the patients with vire-
mia (17 of 32; 53.1%) developed fever without any
other identifiable cause (ie, CMV syndrome). Al-
though there was a trend toward higher peak DNA
loads in patients with CMV syndrome compared
with asymptomatic patients (median, 3.6 log10 cop-
ies/mL [IQR, 3.3-4.2 log10 copies/mL] versus 3.4
log10 copies/mL [IQR, 3.1-4.0 log10 copies/mL]),
this trend was not statistically significant (Figure 1).
Peak CMV DNA loads were higher in the patients
who were treated for CMV reactivation than in those
not treated (median, 3.6 log10 copies/mL; [IQR, 3.3-
4.3 log10 copies/mL] versus 3.3 log10 copies/mL
[IQR, 3.0-3.7 log10 copies/mL]; P 5 .056) (Figure 2).
In addition, persistent viremia (ie, detectable CMV
DNA load in more than 2 sequential plasma speci-
mens) was more prevalent in treated patients com-
pared with untreated patients. Of note, no untreated
patient had evidence of a persistently positive sequen-
tial CMV DNA viral load in plasma specimens.Table 2. Multiple Logistic Regression Analysis of Variables






Yes 0.259 (0.055-1.213) .086
MM disease stage
1 (reference)
2 0.970 (0.153-6.163) .974
3 1.904 (0.383-9.456) .431
Conditioning regimen
M (reference)
M/B/D/T 1.839 (0.223-15.195) .572
M/B/D/G+/2C 0.000 (0.000-0.000) .999
Tandem APBSCT
No (reference)
Yes 5.112 (1.269-20.595) .022







Group 4 (n 5 8)
First APBSCT Second APBSCT
Time to viremia, days, median (IQR)* 13 (3-27) 8 (6-13) 26 (19-34) 10 (6-16) 24 (19-27)
Duration of neutropenia, days, median (IQR)† 10 (7-10) 8 (7-10) 7 (6-8) 6 (5-8) 7 (6-8)
Other infection within 30 days, n (%)‡ 2 (50.0) 7 (63.6) 2 (22.2) 4 (50.0) 4 (50.0)
Peak CMV DNA viral load, log10 copies/mL,
median (IQR)
3.4 (2.9-3.9) 3.7 (3.2-3.9) 3.1 (2.9-3.6) 3.5 (3.4-4.3) 4.3 (3.6-4.6)
CMV viremia associated with fever, n (%) 2 (50.0) 5 (45.5) 5 (55.6) 5 (62.5) 3 (37.5)
Biopsy-proven invasive CMV disease, n (%) 0 (0.0) 0 (0.0) 1 (11.1) 0 (0.0) 0 (0.0)
CMV treatment, n (%)8
No treatment 1 (25.0) 2 (18.2) 4 (44.4) 3 (37.5) 0 (0.0)
Ganciclovir/valganciclovir 3 (75.0) 9 (81.8) 5 (55.6) 3 (37.5) 7 (87.5)
Foscarnet 0 (0.0) 0 (0.0) 0 (0.0) 2 (25.0) 1 (12.5)
Group 1: CMV reactivation after single APBSCT; group 2: CMV reactivation after the first APBSCTof tandem transplantation; group 3: CMV reactivation
after the second APBSCTof tandem transplantation; group 4: CMV reactivation after both the first and the second APBSCTs of tandem transplantation.
*Time from transplantation to development of CMV reactivation.
†Neutropenia is defined as an absolute neutrophil count <500 cells/mL.
‡Confirmed bacterial or fungal infection within 30 days of APBSCT.
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78.1%) were successfully treated with valganciclovir,
ganciclovir, or foscarnet. Invasive colitis was diag-
nosed in 1 patient (of group 3). In addition, there
was a molecularly confirmed case of drug-resistant
CMV infection in a patient who had also undergone
kidney transplantation. None of the patients with un-
treated viremia developed identifiable CMV sequelae.DISCUSSION
CMV establishes lifelong latency within host cells.
Various populations of CD41 and CD81 T cells, as
well as natural killer (NK) cells, are essential to control-
ling this infection [10-12]. In the setting of impaired
cellular immunity, CMV may reactivate from latency,
disseminate, and directly cause life-threatening disease
[13,14]. The virus also encodes multiple proteins that
specifically target and counteract the host immune
response [15]. Based on these immunomodulatoryFigure 1. Comparison of median peak CMV DNA viral loads (log10
copies/mL) in symptomatic and asymptomatic patients with viremia.properties, CMV is thought to indirectly promote
the development of other opportunistic infections
and allograft rejection in some patients [16].
Previous studies that included CD341-selected au-
tologous transplantation recipients reported an overall
incidence of active CMV infection of 26%-39%
[17,18]. We found a much higher overall rate in the
present study (48.5%), including a rate of 63.6% in
seropositive patients who underwent tandem
transplantation with a newer combination chemo-
therapy regimen. There are several potential explana-
tions for the higher prevalence of active CMV
infection in our patient population. First, in older stud-
ies, routine CMV surveillance was done using the pp65
antigenemia assay [17,18], a less-sensitive laboratory
method than real-time PCR. In addition, the use of
newer chemotherapeutic agents as a part of the condi-
tioning regimen likely has a greater impact on CMV-
specific T cell immunity than the use of melphalanFigure 2. Comparison of median peak CMV DNA viral loads (log10
copies/mL) in untreated and treated patients with viremia.
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is associated with bone marrow suppression, including
neutropenia [19], and decreased numbers of T lympho-
cytes, including CD41 T cells [20]. Along with causing
neutropenia, bortezomib diminishes the proliferation
and functionofCD81Tlymphocytes aswell asNKcells
[21]. A previous study found a higher incidence of vari-
cella zoster virus infection in patients treatedwith borte-
zomib [22]. Extrapolating from these observations
suggests that bortezomib use also likely contributed to
the high prevalence of CMV reactivation seen in our
study population. Dexamethasone is well recognized
for its effects on cell-mediated immunity through the in-
hibition and modulation of IL-2, a principal T cell
growth factor [23,24], as well as through the induction
of cellular apoptosis [25]. Thalidomide has both immu-
nostimulatory and immunomodulatory properties,
which include activation of virus-specific CD81 T cells
and NK cells [26,27]. The addition of thalidomide to
other agents does not appear to increase or decrease
the risk of infection in MM patients, however [28].
Finally, the cumulative immunosuppression resulting
from tandem transplantation might additively impact
host susceptibility toCMV.Thispossibility is supported
by our finding thatmore than one-half (53.1%) ofCMV
reactivations occurred after the second of 2 sequential
transplantation. Receipt of a previous APBSCT was
not identified as a significant risk factor for CMV reac-
tivation, however, suggesting that recent immunosup-
pression may be more important than a remote history
of previous transplantation.
CMV reactivation was often associated with fever,
but biopsy-proven invasive disease and/or the develop-
ment of genotypic drug resistance was rare. The low
rates of CMV disease and treatment failure owing to
drug resistance likely reflect the overall efficacy of
prompt preemptive antiviral therapy. None of the 7
patients with untreated CMV reactivation developed
clinical signs or symptoms of invasive disease. Un-
treated patients also tended to have lower CMV
DNA viral loads than treated patients; however, the
substantial overlap in CMV DNA levels between
treated and untreated patients precluded us from de-
termining an optimal CMV DNA viral load threshold
for preemptive treatment. Additional work is needed
to identify those patients with MMmost likely to ben-
efit from early antiviral therapy.
This study has several limitations. First, the combi-
nation of M/B/D/G1/2C likely has significant T cell
immunosuppressive effects; however, use of this condi-
tioning regimen was not associated with CMV reacti-
vation in this study. Sampling bias introduced by the
small number of patients who received M/B/D/G1/
2C is likely. The patients with MM were treated
according to physician preference, which might have
introduced a selection bias. As a result, comparisons
of regimens might be imbalanced by patient factorsnot controlled for in our statistical models. Further-
more, we did not examine CMV-specific immune re-
constitution patterns or measure the recovery of NK
cell function to test our hypothesis that augmented im-
munosuppression from combination conditioning reg-
imens, with or without tandem APBSCT, resulted in
impaired cellular immunity and an increased rate of
CMV reactivation. Previous studies have shown an in-
crease in other bacterial and fungal infections coinci-
dent with CMV infection [29], as well as higher peak
CMV viral loads in symptomatic patients [30].
Although our data show similar trends, our analyses
are limited by the relatively small sample size.
Despite the foregoing limitations, we have clearly
demonstrated a high rate of CMV reactivation after
CD341-selected tandem APBSCT for MM. Preemp-
tive anti-CMV therapy effectively prevented invasive
CMV infection in our cohort and should be consid-
ered, especially when tandem transplantation with
novel chemotherapeutics is planned. Ultimately,
further studies are needed to determine whether the
infectious risks of tandem transplantation outweigh
the potential cancer-related benefits. In addition, pro-
spective studies involving larger numbers of patients
with MM are needed to better define the unique risk
factors for CMV reactivation and invasive disease in
the era of novel combination chemotherapy and tan-
dem transplantation.ACKNOWLEDGMENTS
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